Clinical toxicity associated with tiazofurin

Jean L. Grem, Larry Rubinstein, Susan A. King, Bruce D. Cheson, Michael J. Hawkins, Dale D. Shoemaker

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Tiazofurin, an investigational antimetabolite, is undergoing clinical evaluation in leukemia. We analyzed the data base of 198 patients entered in Phase I trials to characterize the incidence and severity of toxicities associated with tiazofurin according to dose and schedule. Severe myelosuppression occurred infrequently, and was not dose-dependent. A five day bolus schedule had a higher incidence of severe or life-threatening neutropenia than other schedules. Tiazofurin produced lymphopenia which was not dose-dependent in the range of 23-36% decrease from baseline, and the effect on lymphocyte count was generally greater than the decline in neutrophil count. Non-hematologic toxicity of a moderate or worse severity (≥ grade 2) included nausea and vomiting (18% of all courses), serum transaminase elevations (SGOT, 16%; SGPT, 9%), rash (9%), stomatitis (3%), conjunctivitis (3%), headache (10%), other signs of central nervous system toxicity (8%), and cardiac toxicity, primarily pleuropericarditis (4%). Dose-related cutaneous toxicity, headache, and nausea and vomiting were evident in the five day bolus schedule, and myalgia was more frequently reported at higher doses on the single dose schedule. The five day continuous infusion (CI) schedule had a higher incidence of neurotoxicity, cardiac toxicity, SGPT elevations and ocular toxicity than the daily for five days bolus schedule, but none of these differences attained statistical significance. Although the peak plasma concentrations of tiazofurin achieved with the five day bolus schedule were 3-fold higher than the steady-state plasma levels seen with an equal dose given by CI, the area under the concentration-time curve (AUC) was approximately 1.6-fold higher with CI. These observations suggest that both high peak plasma concentrations (above 400 uM) and prolonged exposure to plasma levels exceeding 50 uM may result in a higher incidence of serious non-hematologic toxicity.

Original languageEnglish (US)
Pages (from-to)227-238
Number of pages12
JournalInvestigational New Drugs
Volume8
Issue number2
DOIs
StatePublished - May 1 1990

Fingerprint

tiazofurin
Appointments and Schedules
Incidence
Alanine Transaminase
Nausea
Vomiting
Headache
Antimetabolites
Stomatitis
Lymphopenia
Conjunctivitis
Pericarditis
Myalgia
Lymphocyte Count
Aspartate Aminotransferases
Transaminases
Exanthema
Neutropenia
Leukemia
Neutrophils

Keywords

  • IMP dehydrogenase
  • phase I trials
  • tiazofurin

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Grem, J. L., Rubinstein, L., King, S. A., Cheson, B. D., Hawkins, M. J., & Shoemaker, D. D. (1990). Clinical toxicity associated with tiazofurin. Investigational New Drugs, 8(2), 227-238. https://doi.org/10.1007/BF00177266

Clinical toxicity associated with tiazofurin. / Grem, Jean L.; Rubinstein, Larry; King, Susan A.; Cheson, Bruce D.; Hawkins, Michael J.; Shoemaker, Dale D.

In: Investigational New Drugs, Vol. 8, No. 2, 01.05.1990, p. 227-238.

Research output: Contribution to journalArticle

Grem, JL, Rubinstein, L, King, SA, Cheson, BD, Hawkins, MJ & Shoemaker, DD 1990, 'Clinical toxicity associated with tiazofurin', Investigational New Drugs, vol. 8, no. 2, pp. 227-238. https://doi.org/10.1007/BF00177266
Grem JL, Rubinstein L, King SA, Cheson BD, Hawkins MJ, Shoemaker DD. Clinical toxicity associated with tiazofurin. Investigational New Drugs. 1990 May 1;8(2):227-238. https://doi.org/10.1007/BF00177266
Grem, Jean L. ; Rubinstein, Larry ; King, Susan A. ; Cheson, Bruce D. ; Hawkins, Michael J. ; Shoemaker, Dale D. / Clinical toxicity associated with tiazofurin. In: Investigational New Drugs. 1990 ; Vol. 8, No. 2. pp. 227-238.
@article{9024e91c9628423280179fe02ebc5d70,
title = "Clinical toxicity associated with tiazofurin",
abstract = "Tiazofurin, an investigational antimetabolite, is undergoing clinical evaluation in leukemia. We analyzed the data base of 198 patients entered in Phase I trials to characterize the incidence and severity of toxicities associated with tiazofurin according to dose and schedule. Severe myelosuppression occurred infrequently, and was not dose-dependent. A five day bolus schedule had a higher incidence of severe or life-threatening neutropenia than other schedules. Tiazofurin produced lymphopenia which was not dose-dependent in the range of 23-36{\%} decrease from baseline, and the effect on lymphocyte count was generally greater than the decline in neutrophil count. Non-hematologic toxicity of a moderate or worse severity (≥ grade 2) included nausea and vomiting (18{\%} of all courses), serum transaminase elevations (SGOT, 16{\%}; SGPT, 9{\%}), rash (9{\%}), stomatitis (3{\%}), conjunctivitis (3{\%}), headache (10{\%}), other signs of central nervous system toxicity (8{\%}), and cardiac toxicity, primarily pleuropericarditis (4{\%}). Dose-related cutaneous toxicity, headache, and nausea and vomiting were evident in the five day bolus schedule, and myalgia was more frequently reported at higher doses on the single dose schedule. The five day continuous infusion (CI) schedule had a higher incidence of neurotoxicity, cardiac toxicity, SGPT elevations and ocular toxicity than the daily for five days bolus schedule, but none of these differences attained statistical significance. Although the peak plasma concentrations of tiazofurin achieved with the five day bolus schedule were 3-fold higher than the steady-state plasma levels seen with an equal dose given by CI, the area under the concentration-time curve (AUC) was approximately 1.6-fold higher with CI. These observations suggest that both high peak plasma concentrations (above 400 uM) and prolonged exposure to plasma levels exceeding 50 uM may result in a higher incidence of serious non-hematologic toxicity.",
keywords = "IMP dehydrogenase, phase I trials, tiazofurin",
author = "Grem, {Jean L.} and Larry Rubinstein and King, {Susan A.} and Cheson, {Bruce D.} and Hawkins, {Michael J.} and Shoemaker, {Dale D.}",
year = "1990",
month = "5",
day = "1",
doi = "10.1007/BF00177266",
language = "English (US)",
volume = "8",
pages = "227--238",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Clinical toxicity associated with tiazofurin

AU - Grem, Jean L.

AU - Rubinstein, Larry

AU - King, Susan A.

AU - Cheson, Bruce D.

AU - Hawkins, Michael J.

AU - Shoemaker, Dale D.

PY - 1990/5/1

Y1 - 1990/5/1

N2 - Tiazofurin, an investigational antimetabolite, is undergoing clinical evaluation in leukemia. We analyzed the data base of 198 patients entered in Phase I trials to characterize the incidence and severity of toxicities associated with tiazofurin according to dose and schedule. Severe myelosuppression occurred infrequently, and was not dose-dependent. A five day bolus schedule had a higher incidence of severe or life-threatening neutropenia than other schedules. Tiazofurin produced lymphopenia which was not dose-dependent in the range of 23-36% decrease from baseline, and the effect on lymphocyte count was generally greater than the decline in neutrophil count. Non-hematologic toxicity of a moderate or worse severity (≥ grade 2) included nausea and vomiting (18% of all courses), serum transaminase elevations (SGOT, 16%; SGPT, 9%), rash (9%), stomatitis (3%), conjunctivitis (3%), headache (10%), other signs of central nervous system toxicity (8%), and cardiac toxicity, primarily pleuropericarditis (4%). Dose-related cutaneous toxicity, headache, and nausea and vomiting were evident in the five day bolus schedule, and myalgia was more frequently reported at higher doses on the single dose schedule. The five day continuous infusion (CI) schedule had a higher incidence of neurotoxicity, cardiac toxicity, SGPT elevations and ocular toxicity than the daily for five days bolus schedule, but none of these differences attained statistical significance. Although the peak plasma concentrations of tiazofurin achieved with the five day bolus schedule were 3-fold higher than the steady-state plasma levels seen with an equal dose given by CI, the area under the concentration-time curve (AUC) was approximately 1.6-fold higher with CI. These observations suggest that both high peak plasma concentrations (above 400 uM) and prolonged exposure to plasma levels exceeding 50 uM may result in a higher incidence of serious non-hematologic toxicity.

AB - Tiazofurin, an investigational antimetabolite, is undergoing clinical evaluation in leukemia. We analyzed the data base of 198 patients entered in Phase I trials to characterize the incidence and severity of toxicities associated with tiazofurin according to dose and schedule. Severe myelosuppression occurred infrequently, and was not dose-dependent. A five day bolus schedule had a higher incidence of severe or life-threatening neutropenia than other schedules. Tiazofurin produced lymphopenia which was not dose-dependent in the range of 23-36% decrease from baseline, and the effect on lymphocyte count was generally greater than the decline in neutrophil count. Non-hematologic toxicity of a moderate or worse severity (≥ grade 2) included nausea and vomiting (18% of all courses), serum transaminase elevations (SGOT, 16%; SGPT, 9%), rash (9%), stomatitis (3%), conjunctivitis (3%), headache (10%), other signs of central nervous system toxicity (8%), and cardiac toxicity, primarily pleuropericarditis (4%). Dose-related cutaneous toxicity, headache, and nausea and vomiting were evident in the five day bolus schedule, and myalgia was more frequently reported at higher doses on the single dose schedule. The five day continuous infusion (CI) schedule had a higher incidence of neurotoxicity, cardiac toxicity, SGPT elevations and ocular toxicity than the daily for five days bolus schedule, but none of these differences attained statistical significance. Although the peak plasma concentrations of tiazofurin achieved with the five day bolus schedule were 3-fold higher than the steady-state plasma levels seen with an equal dose given by CI, the area under the concentration-time curve (AUC) was approximately 1.6-fold higher with CI. These observations suggest that both high peak plasma concentrations (above 400 uM) and prolonged exposure to plasma levels exceeding 50 uM may result in a higher incidence of serious non-hematologic toxicity.

KW - IMP dehydrogenase

KW - phase I trials

KW - tiazofurin

UR - http://www.scopus.com/inward/record.url?scp=0025281503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025281503&partnerID=8YFLogxK

U2 - 10.1007/BF00177266

DO - 10.1007/BF00177266

M3 - Article

C2 - 2200759

AN - SCOPUS:0025281503

VL - 8

SP - 227

EP - 238

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -